Improved PFS in patients with GEP-NETs1,3

Since 2017, over half of oncologists initiated treatment with Somatuline® Depot for their newly-diagnosed patients with GEP-NETs and carcinoid syndrome.5*
Lower the risk of disease progression: Consider that active treatment with Somatuline Depot may help improve PFS in appropriate patients.1,3

*Based on IQVIA insurance claims for oncologists with new and continuing patients
during November 2017-October 2022; subject to change without notice.

In adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs.1,3

The Median PFS for Somatuline Depot was not yet reached at 22 months (95% CI NE, NE) compared with 16.6 months for placebo (95% CI: 11.2-22.1).1

Number of events (N=204): Somatuline Depot 32 (31.7%) vs placebo 60 (58.3%).1

CI=Confidence interval. NE=Not reached at 22 months.1


Adverse reactions reported in CLARINET study

Most common adverse reactions (greater than 10%) are abdominal pain, musculoskeletal pain, vomiting, headache, injection site reaction, hyperglycemia, hypertension, and cholelithiasis.1


Please see CLARINET study design and Patient Population Information below.


Study design and patient population information

CLARINET*: A phase III, 96-week, randomized, double-blind, placebo-controlled, pivotal trial1

The majority (84%) of patients in CLARINET had not received prior pharmacologic therapy for GEP-NETs. Some patients (16%) received prior therapy.3

Patients were excluded if they received3:

— An SSA at any time, unless they received it >6 months prior to study entry and for <15 days

— Interferon, chemoembolization, or chemotherapy: <6 months prior to study entry

*CLARINET=Controlled Study of Lanreotide Antiproliferative Response In NeuroEndocrine Tumors.3

Administered every 28 days by deep subcutaneous injection. Follow-up visits occurred at Weeks 12, 24, 36, 48, 72, 96.3

Assessed by a central independent radiological review in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0.3

Disease characteristics

Progression-free survival in the ITT population3

CLARINET included patients with unresectable, well- to moderately-differentiated, locally advanced or metastatic GEP-NETs, a range of hepatic tumor loads, and varying primary tumor locations (foregut/pancreas, midgut, or hindgut).

    • Baseline prognostic characteristics were similar between arms with one exception:
      There were 39% of patients in the Somatuline Depot arm and 27% of patients in the
      placebo arm who had hepatic involvement by tumor of >25%1



    • SOMATULINE DEPOT is contraindicated in patients with hypersensitivity to lanreotide. Allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide.

    Warnings and Precautions

    • Cholelithiasis and Gallbladder Sludge
      • SOMATULINE DEPOT may reduce gallbladder motility and lead to gallstone formation.
      • Periodic monitoring may be needed.
      • If complications of cholelithiasis are suspected, discontinue SOMATULINE DEPOT and treat appropriately.
    • Hypoglycemia or Hyperglycemia
      • Patients treated with SOMATULINE DEPOT may experience hypoglycemia or hyperglycemia.
      • Blood glucose levels should be monitored when SOMATULINE DEPOT treatment is initiated, or when the dose is altered, and antidiabetic treatment should be adjusted accordingly.
    • Cardiovascular Abnormalities
      • SOMATULINE DEPOT may decrease heart rate.
      • In patients without underlying cardiac disease, SOMATULINE DEPOT may lead to a decrease in heart rate without necessarily reaching the threshold of bradycardia.
      • In patients suffering from cardiac disorders prior to treatment, sinus bradycardia may occur. Care should be taken when initiating treatment in patients with bradycardia.

    Most Common Adverse Reactions

    • GEP-NETs: Adverse reactions in >10% of patients who received SOMATULINE DEPOT were abdominal pain (34%), musculoskeletal pain (19%), vomiting (19%), headache (16%), injection site reaction (15%), hyperglycemia (14%), hypertension (14%), and cholelithiasis (14%).
    • Carcinoid Syndrome: Adverse reactions occurring in the carcinoid syndrome trial were generally similar to those in the GEP-NET trial. Adverse reactions in ≥5% of patients who received SOMATULINE DEPOT and at least 5% greater than placebo were headache (12%), dizziness (7%) and muscle spasm (5%).

    Drug Interactions

    • SOMATULINE DEPOT may decrease the absorption of cyclosporine (dosage adjustment may be needed); increase the absorption of bromocriptine; and require dosage adjustment for bradycardia-inducing drugs (e.g., beta-blockers).

    Special Populations

    • Lactation: Advise women not to breastfeed during treatment and for 6 months after the last dose.

    To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or


    SOMATULINE® DEPOT (lanreotide) is a somatostatin analog indicated for:

    • the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival; and
    • the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.

    Please click here for the full Prescribing Information and Patient Information.


    1. Somatuline Depot (lanreotide) Injection [Prescribing Information]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; June 2019.
    2. Data on file. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc.; 2018. This study has been funded by Ipsen.
    3. Caplin ME, Pavel M, Ćwikła JB, et al, for the CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224-233.
    4. Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA; on behalf of the ELECT Study Group. Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial. Endocr Pract.2016;22(9):1068-1080.
    5. Data on file. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc; 2022.
    6. Adelman D, Truong Thanh X-M, Feuilly M, Houchard A, Cella D. Evaluation of nurse preferences between the lanreotide autogel new syringe and the octreotide long-acting release syringe: an international simulated-use study (PRESTO). Adv Ther. 2020.
    7. Data on file. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc.; 2007.
    8. Ryan P, McBride A, Ray D, et al. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis. J Oncol Pharm Pract. 2019;25(6):1425-1433.
    9. Adelman DT, Truong Thanh X-M, Mégret C. Enhancing patient care: co-creation and validation of a new and improved delivery system for lanreotide autogel/depot and its evaluation by US healthcare professionals. Presented at the 101st Annual Meeting and Expo of the Endocrine Society. New Orleans, LA; March 23-26, 2019.
    10. Giving a Subcutaneous Injection. Bethesda, MD: National Institutes of Health Clinical Center; July 2016.
    11. Wolin EM, Manon A, Chassaing C, et al. Lanreotide depot: an antineoplastic treatment of carcinoid or neuroendocrine tumors. J Gastrointest Cancer. 2016;47(4):366-374.